ELUT logo

ELUT

Elutia Inc.NASDAQHealthcare
$1.17-0.85%ClosedMarket Cap: $50.1M

As of 2026-04-06

Valuation

View Details

P/E (TTM)

0.94

PEG

0.00

P/B

1.79

P/S

2.63

EV/EBITDA

-1.85

DCF Value

$-0.21

FCF Yield

-2.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

49.1%

Operating Margin

-150.9%

Net Margin

282.6%

ROE

-225.8%

ROA

85.6%

ROIC

-67.3%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$3.3M$70.8M$1.48
FY 2025$12.3M$53.4M$-0.79
Q3 2025$3.3M$-3.9M$-0.19
Q2 2025$6.3M$-9.6M$-0.26

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.88

Target (Median)

$10.00

Target Range

$5.00 - $10.50

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Lake StreetBuy
2025-09-10
Lake StreetBuy
2025-05-09

Trading Activity

Insider Trades

View All
Williams Michelle LeRouxofficer: CHIEF SCIENTIFIC OFFICER
SellThu Mar 12
Williams Michelle LeRouxofficer: CHIEF SCIENTIFIC OFFICER
SellThu Mar 12
Ferguson Matthewofficer: CHIEF FINANCIAL OFFICER
SellThu Mar 12
Ferguson Matthewofficer: CHIEF FINANCIAL OFFICER
SellThu Mar 12
Mills C Randaldirector, officer: PRESIDENT AND CEO
SellThu Mar 12

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NASDAQ

Beta

0.71

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Peers